BIOMAT Database Logo BIOMAT Database Logo

Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase. 2002

Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Department of Chemistry and Tumor Biology, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA. arthur.taveras@spcorp.com

The 10-bromobenzocycloheptapyridyl farnesyl transferase inhibitor (FTI) Sch-66336 (1) is currently under clinical evaluation for the treatment of human cancers. During structure-activity relationship development leading to 1, 10-bromobenzocycloheptapyridyl FTIs were found to be more potent than analogous compounds lacking the 10-Br substituent. This potency enhancement was believed to be due, in part, to an increase in conformational rigidity as the 10-bromo substituent could restrict the conformation of the appended C(11) piperidyl substituent in an axial orientation. A novel and potent class of FTIs, represented by indolocycloheptapyridine Sch-207758 [(+)-10a], have been designed based on this principle. Although structural and thermodynamic results suggest that entropy plays a crucial role in the increased potency observed with (+)-10a through conformational constraints and solvation effects, the results also indicate that the indolocycloheptapyridine moiety in (+)-10a provides increased hydrophobic interactions with the protein through the addition of the indole group. This report details the X-ray structure and the thermodynamic and pharmacokinetic profiles of (+)-10a, as well as the synthesis of indolocycloheptapyridine FTIs and their potencies in biochemical and biological assays.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010880 Piperidines A family of hexahydropyridines.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D001966 Bromine A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested. Bromine-79,Bromine 79
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.
September 1999, Bioorganic & medicinal chemistry,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.
March 1998, Journal of medicinal chemistry,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
November 1998, Journal of medicinal chemistry,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
August 2005, Molecular pharmacology,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclo hepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase.
July 1999, Bioorganic & medicinal chemistry letters,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.
February 2002, Bioorganic & medicinal chemistry letters,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.
September 2010, Indian journal of pharmaceutical sciences,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
December 1997, Journal of medicinal chemistry,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Stability of tritium-labelled azatadine dimaleate [6,11-dihydro-11 (1-methyl-4-piperidylidine)5H-benzo (5, 6) cyclohepta (1,2-b) pyridine dimaleate] of high specific activity.
January 1977, Radioisotopes,
Arthur G Taveras, and Cynthia Aki, and Jianping Chao, and Ronald J Doll, and Tarik Lalwani, and Viyyoor Girijavallabhan, and Corey L Strickland, and William T Windsor, and Patricia Weber, and Frank Hollinger, and Mark Snow, and Robert Patton, and Paul Kirschmeier, and Linda James, and Ming Liu, and Amin Nomeir
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
January 1991, Journal of medicinal chemistry,
Copied contents to your clipboard!